“…properties such as antiviral (Bader et al, 2008;Bader and Korba, 2010;Jameson et al, 2010;Milazzo et al, 2010) and antitumor activities (Takahashi et al, 2006;Takahashi and Nishibori, 2007;Garwood et al, 2010), however the antitumor molecular mechanisms by which the statin block cancer cell growth are poorly understood (Ghosh-Choudhury et al, 2010), and there are emerging interests to explore the anticancer potentials of HMGCoA reductase inhibitors in the clinical setting, particularly in tumor sites sensitive to these agents in vitro (Chan et al, 2003), some mechanism proposes for anticancer activities are apoptotic inducer, antiangiogenic and antimetastatic. These properties are associates with the inhibition of the synthesis of isoprenoid intermediates of the mevalonate pathway (Slawinska and KandeferSzerszen, 2008 …”